Thymosin alpha-1: what the trials measured

Reviewed 19 sourcesPublished by PepVault

Thymosin alpha-1 trials by the numbers: hepatitis B, sepsis, cancer, COVID-19 and vaccines, each beside its control, and where thymalfasin is approved.

Woman in a lavender sports top pulls a green resistance band looped round a porch post
Last reviewed
Sources
19
Questions
10
Compounds
1

The short answer

Thymosin alpha-1 (thymalfasin, sold as Zadaxin) is a prescription drug abroad, registered in Singapore for chronic hepatitis B and C, and not approved by the FDA. Its best result is in hepatitis B: 40.6% cleared hepatitis B DNA and e antigen from the blood by 18 months, against 9.4% untreated. The largest trial, in 1,106 people with sepsis, found no benefit: 23.4% died, against 24.1% on placebo.

Every number checked at its primary source · · 19 sources · How we research

Evidence: Human trials: randomized trials in hepatitis B, sepsis, melanoma and colorectal cancer, plus pilots and meta-analyses; a 2026 Cochrane review rates the hepatitis B evidence low to very low certainty.

Woman in a lavender sports top pulls a green resistance band looped round a porch post

Where is thymosin alpha-1 approved, and for what?

Thymosin alpha-1 is a peptide first found in the thymus, the gland behind the breastbone where T cells (the immune cells that recognise infected cells) mature. Its drug form is called thymalfasin and is sold as Zadaxin. It is one of the few peptides people discuss online that is a registered prescription medicine somewhere.

Singapore's National Drug Formulary, read on November 20, 2026, lists Zadaxin injection (registration SIN07483P) for chronic hepatitis B, alone or with interferon, and for chronic hepatitis C together with interferon1. Its maker said in February 2010 that Zadaxin was approved in more than 30 countries for a range of uses2.

In the US it has no approval: Drugs@FDA lists no application for thymalfasin4. FDA's page on compounding risks, current as of April 22, 2026, lists thymosin alpha-1 under substances nominated but withdrawn, with the agency's concern that compounded versions may raise immunogenicity, an immune reaction against the drug itself3. Starting thymalfasin, or adding it to treatment for hepatitis, cancer or sepsis, is a decision for your doctor.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault logs each shot with a reminder that fits a twice-weekly schedule, and keeps a side-effect log beside it, so your doctor sees dates next to any change.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What did each trial find, side by side?

The trials split cleanly. Hepatitis B gives the strongest signal, the largest sepsis trial is a clear no, and cancer and COVID-19 sit in between. Each row puts the treated group beside its control.

TrialWhoThymosin alpha-1Control
Chien 1998, randomized598 adults, chronic hepatitis B40.6% cleared viral DNA and HBeAg at 18 months (26-week course)9.4%, no treatment
Naing 2026, Cochrane review of 10 trials71,349 adults, chronic hepatitis BDeaths: risk ratio 0.53 (3 trials, 907 people)Placebo, no treatment or the same co-treatment; very low certainty
ETASS, Wu 20139361 adults, severe sepsis26.0% died by day 2835.0%, usual care (P = 0.062)
TESTS, Wu 2025101,089 adults, sepsis23.4% died by day 2824.1%, placebo
Maio 2010, randomized11488 adults, metastatic melanomaMedian survival 9.4 months6.6 months, dacarbazine plus interferon (P = 0.08)
Niu 2024, randomized12400 adults after colorectal cancer surgeryFewer infections around surgeryMore, chemotherapy alone (P < 0.05)
Shang 2023, 9 studies155,352 adults in hospital with COVID-19Deaths: risk ratio 1.03No difference
Carraro 2012, pilot1894 dialysis patients, H1N1 vaccineMet every EU antibody criterionVaccine alone: weaker day-21 antibodies

A risk ratio is the treated group's risk divided by the control group's: 0.53 means about half the risk, 1.03 means no change.

Does thymosin alpha-1 work for hepatitis B?

This is where it earned its approvals. In Chien's trial, 98 people with chronic hepatitis B got 1.6 mg under the skin twice a week for 26 weeks, the same for 52 weeks, or no treatment5. At 18 months, the complete response (virus DNA cleared from the blood and loss of HBeAg, a marker of active viral copying) was 40.6% after 26 weeks, 26.5% after 52 weeks and 9.4% untreated. None of the responders lost HBsAg, the surface antigen whose loss marks a functional cure.

The odd part is the timing. At the end of treatment the three groups looked alike; the responses kept building after the shots stopped5. A pooled analysis of four trials against interferon, the older standard, saw the same thing: no edge in viral response at the end of 6 months of treatment, then odds of viral response 3.71 times higher 6 months later6. Three of the four trials enrolled HBeAg-negative patients, so that result applies mainly to them.

The 2026 Cochrane review is more cautious. Across 10 trials and 1,349 people, deaths were lower with thymosin alpha-1 (risk ratio 0.53) and serious adverse events were lower too (0.72), but the reviewers rated the certainty very low to low, mainly because the trials were small and open to bias7.

Does it help hepatitis C?

Only as an add-on, and the data are thin. In a pilot of 23 people whose hepatitis C had not cleared on interferon and ribavirin, adding thymalfasin to peginterferon and ribavirin gave a viral response in 60.8% at week 12 and 47.8% at week 24, with no comparison group8. Singapore's label lists hepatitis C only in combination with interferon1. Today's hepatitis C cure is a course of direct-acting antivirals, which these trials predate.

Did thymosin alpha-1 lower deaths in sepsis?

No, once a large blinded trial asked. Sepsis is organ failure driven by the body's response to an infection, and it often leaves the immune system worn out, the gap thymosin alpha-1 was meant to fill. The ETASS trial in six Chinese hospitals randomized 361 people with severe sepsis: 26.0% died within 28 days on thymosin alpha-1 against 35.0% on usual care, a result just short of the usual cut-off for chance (P = 0.062)9.

TESTS was built to settle it: 22 centres, 1,106 adults, double blinded against placebo, 1.6 mg under the skin every 12 hours for seven days10. Deaths at 28 days were 23.4% against 24.1%, a hazard ratio of 0.97 (the treated group's rate of death relative to placebo's) in the corrected paper, and no secondary or safety outcome differed10. In a planned subgroup analysis, people with diabetes fared better (hazard ratio 0.58) and people under 60 fared worse (1.67), though the under-60 gap shrank to 1.45 and lost significance once organ support before randomisation was accounted for. The authors read these as leads for further research; the main answer stands: no lower mortality.

What happened in the cancer trials?

In the cancer trials it was given beside chemotherapy, not alone. The largest randomized trial gave 488 people with metastatic melanoma dacarbazine chemotherapy with interferon, thymosin alpha-1 or both11. The two arms with 3.2 mg had 10 and 12 tumour responses against 4 in the control arm, and median survival was 9.4 months with thymosin alpha-1 against 6.6 months on dacarbazine and interferon, a gap that fell short of significance (P = 0.08). It added no toxicity.

After colorectal cancer surgery, 400 patients randomized to XELOX chemotherapy with thymalfasin had fewer infections around surgery, fewer complications and longer disease-free survival than those on chemotherapy alone12; twice and three times a week did equally well on infections. In a 2026 stomach cancer study, 30 patients on thymalfasin plus immunotherapy and chemotherapy before surgery had no cancer left in the removed tissue in 30.0% of cases, but with no comparison group, thymalfasin's own share is unknown13.

Did it work for COVID-19?

The answer depends on which studies you pool, and that is the honest finding. One meta-analysis of 8 studies in moderate to critical COVID-19 found lower deaths (risk ratio 0.59) but no less ventilator use14. Another, of 9 studies and 5,352 patients, found no effect on deaths (risk ratio 1.03) and concluded the data do not support using it in hospital; a benefit showed only in subgroups such as patients over 60 and the severely ill15.

The randomized data are small. A randomized pilot in 49 hospitalized patients saw faster recovery that did not reach significance, and among those on low-flow oxygen, treated patients gained 3.84 times more CD4+ T cells (helper immune cells) from day 1 to day 5 than controls16. In dialysis patients, an early report counted 3 deaths on thymalfasin against 7 in controls among 194 randomized, with the full results still to come17.

Does thymosin alpha-1 boost vaccine response?

In people whose immune systems answer vaccines weakly, an early trial says yes. In an Italian pilot, dialysis patients got the pandemic H1N1 flu vaccine alone or with 3.2 or 6.4 mg of thymalfasin18. Both thymalfasin groups had higher antibody levels at day 21 than the vaccine-only group and fully met the European regulator's licensing criteria for a pandemic vaccine; no adverse event was tied to thymalfasin. The authors call for larger trials.

Why twice a week in hepatitis but twice a day in sepsis?

The two schedules answer different questions. Singapore's label gives 1.6 mg under the skin twice a week for 6 to 12 months in hepatitis B1, the schedule of the Chien trial5, and notes responses that arrive 12 months or more after treatment ends1. The drug itself clears fast: in healthy volunteers it peaked 1 to 2 hours after a shot under the skin, with a half-life (the time for half a dose to leave the blood) under 3 hours and no build-up over 5 days of dosing19; the TESTS authors give 1.5 hours10. For sepsis they chose 1.6 mg every 12 hours for a week, citing an earlier study in which 3.2 mg a day helped and 1.6 mg a day did not10.

Try it

How Thymosin Alpha-1 builds up

An estimate from a half-life of about 2 hours, one dose a day for four weeks. The shape of the level, not a measurement.

Try your own scheduleThymosin Alpha-1 in the library

What side effects did the trials report?

Very few, which is its most consistent finding. Chien's hepatitis B trial saw no significant side effects5, the melanoma trial saw no added toxicity11, and ETASS recorded no serious drug-related event9. In TESTS, adverse events came to 66.4% on thymosin alpha-1 and 67.6% on placebo, and serious ones to 26.8% against 29.3%, in intensive care patients whose illness causes most of them10.

Singapore's label adds two points1. In hepatitis B, a temporary rise in the liver enzyme ALT to more than twice its starting level, a flare, can happen during treatment; the label generally continues treatment through it unless signs of liver failure appear. And it is not for people allergic to it, or for people whose immune system is deliberately suppressed, such as transplant patients, unless the benefit clearly outweighs the risk.

Commonly reported: little to feel day to day. People who post about it judge it over a season, by fewer or shorter colds.

PepVault logs each shot with a reminder that fits a twice-weekly schedule, and keeps a side-effect log beside it, so your doctor sees dates next to any change. Log it in PepVault

When to get help Yellowing of the skin or eyes, dark urine or new confusion during hepatitis B treatment can be signs of the liver failure the label watches for, and a reason to contact your doctor promptly1.

Track it in the app

Sources

  1. National Drug Formulary (Government of Singapore). Zadaxin injection, SIN07483P: product information. Read November 20, 2026. ndf.gov.sg
  2. SciClone Pharmaceuticals and Sigma-Tau. Press release on Zadaxin and the H1N1 vaccine study. February 8, 2010. biospace.com
  3. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of April 22, 2026. fda.gov
  4. U.S. Food and Drug Administration. Drugs@FDA (openFDA) search for thymalfasin: no matches. Read November 20, 2026. api.fda.gov
  5. Chien RN et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 1998. PubMed 9581695
  6. Yang YF et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res. 2008. PubMed 18078676
  7. Naing C et al. Thymosin-α1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026. PubMed 42713852
  8. Poo JL et al. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment. J Gastroenterol Hepatol. 2004. PubMed 15546256
  9. Wu J et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013. PubMed 23327199
  10. Wu J et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025 (corrected May 30, 2025, BMJ 2025;389:r1098). PubMed 39814420
  11. Maio M et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol. 2010. PubMed 20194853
  12. Niu W et al. A prospective and randomized control study on effects of thymalfasin for injection on perioperative immune function and long-term prognosis of patients with colorectal cancer. Biotechnol Genet Eng Rev. 2024. PubMed 37248723
  13. Xu H et al. Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial. BMC Med. 2026. PubMed 41749205
  14. Soeroto AY et al. The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Inflammopharmacology. 2023. PubMed 37845598
  15. Shang W et al. Thymosin alpha1 use in adult COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Int Immunopharmacol. 2023. PubMed 36527881
  16. Shehadeh F et al. A pilot trial of thymalfasin (thymosin-α-1) to treat hospitalized patients with hypoxemia and lymphocytopenia due to COVID-19 infection. J Infect Dis. 2023. PubMed 36056913
  17. Tuthill CW et al. A pilot trial of thymalfasin (Ta1) to prevent COVID-19 infection and morbidities in renal dialysis patients: preliminary report. Int Immunopharmacol. 2023. PubMed 36881981
  18. Carraro G et al. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. Vaccine. 2012. PubMed 22178096
  19. Rost KL et al. Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers. Int J Clin Pharmacol Ther. 1999. PubMed 10027483

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo